Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
HCM
HCM
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
HCM News
HUTCHMED to Present New Data at ASCO Meeting
May 22 2026
Newsfilter
HUTCHMED and Innovent's Drug Combination Approved in China
May 21 2026
NASDAQ.COM
HUTCHMED and Innovent Jointly Approved New Drug
May 21 2026
Newsfilter
Virtual Investor Conference Presentations Now Available Online
Apr 29 2026
Globenewswire
Deutsche Bank to Host Depositary Receipts Investor Conference
Apr 23 2026
Globenewswire
HUTCHMED to Present New Data on HMPL-A580 at AACR 2026
Apr 09 2026
Newsfilter
HUTCHMED Initiates Phase III Trial for HMPL-760
Mar 23 2026
NASDAQ.COM
HUTCHMED Announces Withdrawal of TAZVERIK® from Chinese Market
Mar 09 2026
Newsfilter
HUTCHMED Board Member Changes Announced
Mar 06 2026
Newsfilter
HUTCHMED Reports $457 Million Net Income for 2025 Amid Strategic Growth
Mar 05 2026
Newsfilter
HUTCHMED Reports FY 2023 Financial Results
Mar 05 2026
seekingalpha
HUTCHMED Initiates Phase I/IIa Trial for HMPL-A580
Mar 04 2026
Newsfilter
HUTCHMED to Announce 2025 Final Results on March 5
Feb 06 2026
Newsfilter
HUTCHMED and AstraZeneca's MET Inhibitor Approved, PFS Improved to 8.2 Months
Jan 14 2026
Globenewswire
HUTCHMED and AstraZeneca's Drug Approved, PFS Increased to 8.2 Months
Jan 14 2026
Newsfilter
ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis
Jan 09 2026
NASDAQ.COM
Show More News
